Abstract
CDK4/6 inhibitors not only induce cell-cycle arrest but also promote antitumor immunity by stimulating the production of type III interferons, which enhance tumor antigen presentation, and suppress regulatory T cells. The immune effects of these drugs provide a rationale for combining CDK4/6 inhibitors with checkpoint blockade agents.
- ©2017 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst September 1, 2017
doi: 10.1158/2159-8290.CD-NB2017-122
CDK4/6 Inhibitors Induce Antitumor Immunity
Permalink:
Jump to section
Advertisement